Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

21.40 +0.18 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
MarketBeat Week in Review – 3/6 - 3/10
Stocks are down sharply to end the week, and the MarketBeat staff continues to show investors why dividend stocks need to be part of your playbook 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Analyst Expectations for Schrodinger's Future
Via Benzinga
3 Amazing AI Stocks for Your March Buy List
With the Street catching onto the transformational power of AI, these amazing AI stocks are very well-positioned to climb tremendously. 
Via InvestorPlace
Why Shares of Schrödinger Were Up Today
The company delivered a nice earnings surprise. 
Via The Motley Fool
Citigroup Maintains Buy Rating for Schrodinger: Here's What You Need To Know
Via Benzinga
4 Analysts Have This to Say About Schrodinger
Via Benzinga
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results
From Schrödinger, Inc.
Via Business Wire
3 AI Stocks to Buy for the Future of Automation
Increased appreciation for AI and the Street's reduced hostility to growth stocks make this a good time to find AI stocks to buy. 
Via InvestorPlace
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
From Schrödinger Inc.
Via Business Wire
Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28
From Schrödinger
Via Business Wire
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a... 
Via Talk Markets
Schrödinger to Present at SVB Securities Global Biopharma Conference
From Schrödinger
Via Business Wire
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... 
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities
From Schrödinger, Inc.
Via Business Wire
Why These 7 Healthcare Stocks Could Soar in 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
7 Drug Stocks That Will Soar in 2023
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years. 
Via InvestorPlace
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting
From Schrödinger
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 49 companies made new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback